Terms: = Prostate cancer AND PTPRB, ENSG00000127329, 5787, MGC142023, DKFZp686H15164, MGC59935, PTPB, HPTP-BETA, P23467, HPTPB, R-PTP-BETA, FLJ44133, DKFZp686E2262 AND Treatment
3 results:
1. Long-Term Outcomes of a Prospective Study on Highly Hypofractionated Intensity Modulated Radiation Therapy for Localized prostate cancer for 3 Weeks.
Nakamura K; Ikeda I; Inokuchi H; Aizawa R; Ogata T; Akamatsu S; Kobayashi T; Mizowaki T
Pract Radiat Oncol; 2023; 13(6):e530-e537. PubMed ID: 37414247
[TBL] [Abstract] [Full Text] [Related]
2. Anti-androgen therapy induces transcriptomic reprogramming in metastatic castration-resistant prostate cancer in a murine model.
Zhao Y; Peng X; Baldwin H; Zhang C; Liu Z; Lu X
Biochim Biophys Acta Mol Basis Dis; 2021 Jul; 1867(7):166151. PubMed ID: 33892077
[TBL] [Abstract] [Full Text] [Related]
3. A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802.
DiPaola RS; Chen YH; Bubley GJ; Stein MN; Hahn NM; Carducci MA; Lattime EC; Gulley JL; Arlen PM; Butterfield LH; Wilding G
Eur Urol; 2015 Sep; 68(3):365-71. PubMed ID: 25533418
[TBL] [Abstract] [Full Text] [Related]
